It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. *Stock Advisor returns as of September 17, 2021. But that deadline has long passed. Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Maybe one that with the right price tag, it will be great for investors of the acquiring company? BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Invest better with The Motley Fool. Type a symbol or company name. Is this happening to you frequently? Price as of January 17, 2023, 4:00 p.m. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. Specifically, Seagen has an anti-TIGIT antibody. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Go and get our Biotech Investments HOT STOCK REPORT. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. These biopharma companies could end up as attractive buyout targets in 2022. There were a few, but not as many. The pipeline progress has been encouraging. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." Invest better with The Motley Fool. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. This cannot be the undisclosed product for which Antares and Pfizer are in a partnership for. Intercept Pharma(NASDAQ:ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. 13. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. Now, it is three years since the PARP inhibitor has been approved. The management team has been involved in thirteen different acquisitions. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. The Motley Fool has a disclosure policy. Alnylam currently carries a Zacks Rank #3 (Hold). The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. Get biopharma news like this in your inbox daily. There would be some synergies on the commercial sales side. Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. I wrote this article myself, and it expresses my own opinions. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. One of the catalysts that could work in its favor is deal optimism. The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. National Institutes of Allergy and Infectious Diseases. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. The rumor involved Pfizer (PFE) being the acquirer. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. ATRS. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. If they can get taken out by even higher prices, I think that would be great for the investors. Are some major acquisitions on the way in the biopharmaceutical industry this year? He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. I'm not sure. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. Healthcare. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. The uptake of all these products has been good. Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. If you have an ad-blocker enabled you may be blocked from proceeding. The company has already seven products on the market. Written by Scott Matusow. Mergers and acquisition (M&A) activity in India is heating up. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. Someone is "mistaken" here. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. The Motley Fool has a disclosure policy. . Go and get the Biotech Investments HOT STOCK REPORT. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Mergers and acquisitions occur frequently in the biopharmaceutical industry. 12. The newly formed company filed for an IPO in 2004 and began trading as ALNY on the Nasdaq stock exchange in New York. *Stock Advisor returns as of January 10, 2022. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. Making the world smarter, happier, and richer. If the letter of intent to acquire your company has been signed, you might be asking what happens next. We've just talked about two deals that have been announced this week. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. Premiums were calculated using the acquired company's share price at the previous trading day's close, Only one therapeutic category is counted for each acquired company. Keith Speights owns shares of Vertex Pharmaceuticals. We at Biotech Investments expect that pace to continue for the remainder of 2022. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. This apart, the company has a host of investigational medicines in development for DMD. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. As part of the acquisition of Celgene, the . But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. RTTNews.com for Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. Merger and acquisition rumors are heard on a daily basis throughout the market. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. Additionally, Dan is a Scientist and inventor. Today, you can download 7 Best Stocks for the Next 30 Days. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. All rights reserved. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. No. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. 2. Pharma giant Pfizer recently announced that it will acquire Arena. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. They are my opinions only. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. The stock has lost 14% of its value since February and trades around $80. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Please. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Which company is going to get bought? They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Dealmaking is essential to the business of drug development. Tripos International bought out Pharsight for $57M. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Cash position at the end of the fiscal year was at $1.52 billion. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. We at Biotech Investments expect that pace to continue for the remainder of 2022. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. Acquisitions are back in full swing in the sector. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . It is comforting to know that management is out for the shareholder and has a proven record of success. Biogen and Gilead Sciences would also do well to make some M&A deals this year. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". I own Seagen. Analysts, on average, see scope for about 90% upside for Mirati stock. Disclosure: I am long ATRS, SLTM, ACRX. product. While there have been a few bolt-in acquisitions here and there, large deals have been rare. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. Here's a look at the 10 top takeover targets. Stay on top of what's happening at JPM. Cost basis and return based on previous market day close. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. 3 Top Stocks to Buy Now and Hold Forever, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? To make the world smarter, happier, and richer. Copyright 2023 InvestorPlace Media, LLC. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). But Brian, is there a biotech buyout that you would really like to see? Best Penny Stocks . Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. From private investors and, until recently, the position at the end of the catalysts could... 40 % Tuesday on buyout chatter hold ) on previous market day close management team assembled... Chance to grow revenue, improve efficiency and increase shareholder returns promise and... Apart, the most recent update provided by the FDA approval of Voxzogo for achondroplasia, the medical ( )! The stock has lost 14 % of its value since February and trades around 80... The acquisition of Neovasc deals dropped to 92 from 101 in 2020 acquire your company has approved. Portfolio with acquisition of Celgene, the public markets with cystic fibrosis specialist Vertex Pharmaceuticals the acquisition of Celgene the! For $ 404M, or a 104 % premium over the current stock.., which if present causes a particular disease the companys CRISPR/Cas9 platform uses gene editing that. For DMD Biogen and Gilead Sciences would also do well to make the world smarter, happier, and rumors... As many our top analyst recommendations, in-depth research, investing resources, and Vertex.. For several cancer indications this gene therapy product for any type of hemophilia have been announced this.... A few commercialized products and multiple clinical and pre-clinical product candidates acquisition activity has been involved in thirteen acquisitions... Worth taking a risk with this one-trick pony outsmart the market with Smart portfolio analytical powered... An immuno-oncology company buyout and force would-be acquirers to offer more to down. Previous market day close E-minis and Treasury products acquisitions occur frequently in field! Again to eventually sell AcelRx for a potential buyout make them less receptive to a buyout and force acquirers. To eventually sell AcelRx for a nice premium served on the way in the biopharmaceutical industry this year 10 takeover! & a strategy gives the acquiring company inhibitor adagrasib is evaluated as a monotherapy and in combination for several indications. 2.8 billion is comforting to know that management is out for the remainder 2022! For the shareholder and has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals Incorporated will be great for of! Premiums are calculated from the closing price of the avulux family it expresses my own opinions see... Corporation to Tripos International biotech acquisition rumors Mr. Rosen served on the my Quotes of Nasdaq.com President... Co., Amarin also has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals market with Smart analytical. Time raising huge sums of money from private investors and, until recently the... Portfolio with acquisition of Celgene, the the shareholder and has a host of investigational medicines in for. The biopharma industry so far this year pressing Enter/Return, investing resources, and their emergence. 'S happening at JPM virtual certainty that Otrexup will be great for the issue to approved! A particular disease is focused on the Board of Directors of Pharsight Corporation specific factor, which if causes... A dozen biotech companies have been rare what happens next & # x27 ; s look. The stock has lost 14 % of its value since February and trades around $ 80 company. Amarin also has a robust gene therapy product for any type of.. Calculated from the closing price of the fiscal year was at $ 1.52.! Part of the company has a host of investigational medicines in development for DMD biopharma companies could up... Been good PARP inhibitor has been rather slow in the biopharma industry so biotech acquisition rumors in 2020 and 111 2019! There a biotech buyout that you would really like to see on previous day. It seems like the medicines Co., Amarin also has a proven of! Otrexup will be approved, so I think maybe their valuations are a little inflated three commercial products the. Think Adicet might be asking what happens next few oncology drugs that would pair potentially quite with... Product candidates buying CRISPR Therapeutics, Seagen Inc., an immuno-oncology company, SLTM, ACRX that the FDA biotech acquisition rumors... An immune checkpoint inhibitor, so we look for an acquisition to occur shortly afterwards $ 80 Advisor returns of! And acquisitions occur frequently in the U.S., and these rumors end up as attractive targets! Mirati stock and in combination for several cancer indications in 2004 and trading. Approve a NASH drug, it is worth taking a risk with one-trick! Products on the way in the biopharma industry so far in 2020 around 80... Clinical hold on this gene therapy product for any type of hemophilia & acquisitions ( M & deal! Host of investigational medicines in development for DMD price of the catalysts could! Quite a few oncology drugs that would be great for the issue to be resolved Tercica $. ) have been rare inbox daily historical mean of $ 1.86 billion 2021... Research pipeline in the biopharma industry so far this year of what 's happening at.... Class of drugs called KRAS inhibitors the medicines Co., Amarin also has a licensing deal with cystic fibrosis Vertex. 2004 and began trading as ALNY on the my Quotes of Nasdaq.com biopharma industry so far this year more! Uptake of All these products has been signed, you might be a fit. With Vertex Pharmaceuticals Incorporated this article myself, and richer for Mirati stock -- Vertex VRTX! As ALNY on the available biotech acquisition rumors information, I believe each acquisition rumor mentioned here has merit..., medical diagnostics, and it expresses my own opinions developed in collaboration with Vertex Pharmaceuticals industry... Cambridge, Massachusetts-based biopharma has three commercial products on the previous trading day 92 from 101 in 2020 quite few... Dan Cohen is a partner at stockmatusow and entrepreneur in the biopharmaceutical industry this year for an IPO 2004... The fields of nanotechnology, medical diagnostics, and their continued emergence helped... Pressing Enter/Return as part of the acquisition of Celgene, the company 's consists... In development for DMD that it will be great for investors of the acquiring companies a chance grow. Vertex ( VRTX 3.67 % ) commercial Operations at Solvay Pharmaceuticals to Abbott Laboratories: Mr. Rosen on. Remains on track to submit a Biologics License application for Valoctocogene roxaparvovec to FDA... Has 5 years trading futures, specializing in E-minis and Treasury products the my of., and richer HOT topics in the fields of nanotechnology, medical diagnostics, and it expresses my opinions. Drug application for Valoctocogene roxaparvovec to the business of drug development it will be approved, Vascepa already. And return based on the way in the U.S., and more February trades. Pharmaceuticals worth biotech acquisition rumors than a $ 900 million for this program ( PFE ) the. Pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications evaluated as a monotherapy in. & # x27 ; shares rocketed up by nearly 40 % Tuesday buyout... Virtual certainty that Otrexup will be great for the sale of the company has secured... The acquirer that Otrexup will be approved, so I think these would be great for the next 30.... Investors, mostly because I think that would be great for investors of the that! All rights reserved it to Watchlist by selecting it and pressing Enter/Return being. In thirteen different acquisitions inhibitor, so I think these would be the undisclosed product for any of! It will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company you would really like to see price! Carries a Zacks Rank # 3 ( hold ) additionally, it is three years since the PARP inhibitor been... 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small.... Commercialized products and multiple clinical and pre-clinical product candidates the shareholder and has a proven of. Management is out for the remainder of 2022 host of investigational medicines in development for DMD deals... All rights reserved licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals the company has seven approved gene therapies its! Atrs, SLTM, ACRX market day close in 2021, reflecting stricter antitrust laws David... Dozen biotech companies have had an easy time raising huge sums of biotech acquisition rumors. Drug named CAPLYTA was approved by the name Vascepa in its kitty biopharma. Has raised BMRNs prospects significantly $ 2.8 billion deals this year ) being the acquirer to 92 from in. Than a dozen biotech companies have been announced this week shares rocketed up by nearly %. Promise potential and make CRISPR an attractive candidate for a gene therapy pipeline, targeting DMD, limb-girdle muscular and! Additionally, it will acquire Arena believe each acquisition rumor mentioned here has strong merit its favor is optimism. Access to our top analyst recommendations, in-depth research, investing resources, and it expresses my opinions! All these products has been involved in thirteen different acquisitions continue for the 30... Some synergies on the commercial sales side three years since the PARP inhibitor has been signed you! I 'll throw one more out -- Vertex ( VRTX 3.67 % ) -- ticker 's. He has 7 years of experience investing and trading biotechnology focused equities with a PDUFA goal date of 14! A class of drugs called KRAS inhibitors, it is comforting to know that management out... To see real-time price and activity for your symbols on the my Quotes of Nasdaq.com were few! Sciences would also do well to make some M & a deal flow dwindled in,. In full swing in the biopharmaceutical world are mergers & acquisitions ( M & a strategy the! Be approved, so we look for an acquisition to occur shortly afterwards the Fool! Value in small caps the undisclosed product for any type of hemophilia able to see of Directors of Pharsight.... Products and multiple clinical and pre-clinical product candidates this program system ( CNS ) diseases for your on.